Additionally, HDAC inhibitors downregulate PD-L1 expression in melanoma [169], liver cancer [170], anaplastic thyroid cancer [171], NSCLC [172] and triple-negative breast cancer [173] which subsequently enhance and potentiate immunotherapy response. Here, CD274 is linked to non-small cell lung carcinoma.